Geron Co. (NASDAQ:GERN) Shares Purchased by Sei Investments Co.

Sei Investments Co. boosted its position in Geron Co. (NASDAQ:GERN) by 6.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 189,614 shares of the biopharmaceutical company’s stock after purchasing an additional 12,027 shares during the quarter. Sei Investments Co.’s holdings in Geron were worth $671,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp raised its position in shares of Geron by 28.4% in the third quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock valued at $131,486,000 after buying an additional 6,413,204 shares during the last quarter. World Investment Advisors LLC raised its holdings in Geron by 10,151.4% in the 3rd quarter. World Investment Advisors LLC now owns 1,029,553 shares of the biopharmaceutical company’s stock valued at $4,674,000 after acquiring an additional 1,019,510 shares during the last quarter. Exome Asset Management LLC purchased a new position in Geron in the 3rd quarter worth approximately $4,109,000. Barclays PLC boosted its holdings in shares of Geron by 114.9% during the 3rd quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock worth $5,902,000 after purchasing an additional 694,931 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Geron by 4.7% in the third quarter. Wellington Management Group LLP now owns 12,662,404 shares of the biopharmaceutical company’s stock valued at $57,487,000 after purchasing an additional 570,580 shares in the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Price Performance

Shares of GERN opened at $1.28 on Wednesday. The firm has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $3.21. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. Geron Co. has a 1-year low of $1.26 and a 1-year high of $5.34. The stock has a market cap of $815.24 million, a PE ratio of -4.00 and a beta of 0.66.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. As a group, analysts forecast that Geron Co. will post -0.25 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Geron in a research report on Wednesday, March 12th. HC Wainwright reiterated a “neutral” rating on shares of Geron in a report on Wednesday, March 12th. Stifel Nicolaus lowered their price target on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Barclays restated an “overweight” rating and set a $4.00 price objective (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. Finally, Scotiabank decreased their target price on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.75.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.